Irsogladine: Overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract

Current Pharmaceutical Design

Volumn 19, Issue 1, 2013, Pages 106-114

  Akagi, Michiyo ^a   Amagase, Kikuko ^a   Murakami, Toshiko ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anti ulcer drug; Gastric and intestinal lesion; Healing promoting action; Irsogladine; Mucosal protection

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; AMPICILLIN; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIMYCIN; CELECOXIB; CILOSTAMIDE; CYCLIC AMP; FAMOTIDINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GEFARNATE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INDOMETACIN; IRSOGLADINE MALEATE; ISOBUTYLMETHYLXANTHINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHODIESTERASE; REACTIVE OXYGEN METABOLITE; REBAMIPIDE; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; TEPRENONE; UNINDEXED DRUG; VINPOCETINE; ZYMOSAN;

ANTIULCER ACTIVITY; APHTHOUS ULCER; BIOSYNTHESIS; CELL COMMUNICATION; CELL LEVEL; CELL PROTECTION; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GAP JUNCTION; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA PROTECTION; HELICOBACTER PYLORI; HUMAN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; PROTECTION; REVIEW; SMALL INTESTINE DISEASE; STOMACH LESION; STOMACH MUCOSA BLOOD FLOW; STOMACH PROTECTION; STOMACH ULCER; TIGHT JUNCTION; ULCER HEALING; ULCERATIVE COLITIS;

EID: 84873970974     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811306010106     Document Type: Review

References (69)

1. Ueda F, Kameda Y, Yamamoto O, et al. Beta-adrenergic regulation of gap-junctional intercellular communication in cultured rabbit gastric epithelial cells. J Pharmacol Exp Ther 1994; 271: 397-402.
2. Kameda Y, Ueda F. Irsogladine inhibits ionomycin-induced decrease in intercellular communication in cultured rabbit gastric epithelial cells. Jpn J Pharmacol 1995; 69: 223-8.
3. Ando T, Momota K, Sugiyama M. Absorption, distribution and excretion of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate in rats, dogs and monkeys. Arzneimittelforschung 1986; 36: 1221-8.
4. Hara A, Murata T, Uemura R, et al. Identification of connexins in human oral mucosa and therapeutic effect of irsogladine maleate on aphthous stomatitis. J Gastroenterol 1999; 34: 1-6.
5. Yoshida T. Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis. J Rheumatol 2003; 30: 2082-3.
6. Nanke Y, Kamatani N, Okamoto T, et al. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an openlabel, single-centre study. Drugs RD 2008; 9: 455-9.
7. Hiraishi H, Haruma K, Miwa H, et al. Clinical Trial: Irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection; results of a multicentre, double-blind, randomised clinical trial (IMPACT study). Aliment Pharmacol Ther 2010; 31: 824-33.
8. Murakami K, Okimoto T, Kodama K, et al. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: A randomized, controlled, prospective study. Scand J Gastroenterol 2010; 46: 287-92.
9. Kamei K, Kubo Y, Kato N, et al. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 2008; 53: 2657-66.
10. Okabe S, Nakagawa K. Effect of irsoglandine maleate on the aspirin-induced intestinal lesions in rats. Jpn Pharmacol Ther 2010; 38: 297-302.
11. Kuramoto T, Umegaki E, Kojima Y, et al. Irsogladine, a Gastroprotective Drug, Protects Against NSAID-Induced Esophagitis, Peptic Ulcers, and Small Intestinal Mucosal Damages in Healthy Subjects: A Prospective Randomised Study of Comparison With Omeprazole. Gastrointest Endosc 2011; 73 (Suppl): AB445.
12. Nakagawa T, Noguchi Y, Mandai Y et al, Tight Junction Protein Regulation is Important to Ameliorate the Inflammation of Colitis in Interleukin-10 Gene-Deficient (IL-10 Ko) Mice. Gastroenterology 2011; 140 (Suppl 1): S-518
13. Yamaguchi H, Suzuki K, Nagata M, et al. Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium. Med Mol Morphol, in Press
14. Aihara E, Ise F, Ohashi Y, et al. Development of antral lesions induced by alendronate in rat stomachs: Effect of irsogladine maleate. Jpn Pharmacol Ther 2007; 35: 587-99.
15. Takeuchi K, Tanaka A, Nukui K, et al. Aggravation by paroxetine, a selective serotonin reuptake inhibitor, of antral lesions generated by nonsteroidal anti-inflammatory drugs in rats. J Pharmacol Exp Ther 2011, 338: 850-9.
16. Izuhara C, Takayama S, Yamada N, et al. Aggravation by clopidogrel, an antiplatelet drug, of HCl/aspirin-induced gastric hemorrhagic lesions in rats: Prophylactic effect of irsogladine. Jpn Pharmacol Ther 2011; 39: 421-35.
17. Takayama S, Izuhara C, Yamada N, Yamanaka S, Hashimoto E, Kaneko S, and Takeuchi K. A new model of gastric bleeding induced in rats by aspirin plus clopidogrel under stimulation of acid secretion: Prophylactic effects of antiulcer drugs. J Physiol Pharmacol 2012; 63: 41-52.
18. Bender AT, Brevo JA. Cyclic Nucleotide Phosphodiesterase: Molecular Regulation to Clinical Use. Pharmacol Rev 2006; 58: 488-520.
19. Kyoi T, Oka M, Noda K, et al. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci 2004; 75: 833-42.
20. Yamamoto H, Umeda M, Mizoguchi H, et al. Protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats: A comparative study with rebamipide. World J Gastroenterol 1999; 5: 477-82.
21. Saez JC, Berthoud VM, Branes MC, et al. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 2003; 83: 1359-400.
22. Laird DR. Life Cycle of connexins in health and desease. Biochem J 2006; 394: 527-43.
23. Sawada N, Murata M, Kikuchi K, et al. Tight junctions and human diseases. Med Electron Microsc 2003; 36: 147-56.
24. Kawasaki Y, Tsuchida A, Sasaki T, et al. Irsogladine malate upregulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas 2002; 25: 373-7.
25. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32: 200-219.
26. Takakuwa Y, Kokai Y, Sasaki K, et al. Bile canalicular barrier function and expression of tight-junctional molecules in rat hepatocytes during common bile duct ligation. Cell Tissue Res 2002; 307: 181-9.
27. Uzzau S, Cappuccinelli P, Fasano A. Expression of Vibrio cholerae zonula occludens toxin and analysis of its subcellular localization. Microb Pathol 1999; 27: 377-85.
28. Mori M, Sawada N, Kokai Y, et al. Role of tight junctions on the occurrence of cancer invasion and metastasis. Med Electron Microsc 1999; 32: 193-8.
29. Morita H, Katsuno T, Hoshimoto A, et al. Irsogladine, An activator of Gap-junctional intercellular communication, suppresses paracellular permeability of human intestinal epithelial cell monolayers through up-regulation of claudin-4. Gastroenterology 2006; 130 (Suppl 2): 241.
30. Farkas R, Pronai L, Tulassay Z, et al. Relationship between eradication of Helicobacter pylori and gastric mucosal superoxide dismutase activity. Anticancer Res 2005; 25: 4763-7.
31. Sánchez S, Martín MJ, Ortiz P, et al. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac. Dig Dis Sci 2002; 47: 1389-98.
32. Kyoi T, Noda K, Oka M, et al. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci 2004; 76: 71-83.
33. Sato M, Manabe N, Hata J, et al. Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs. Digestion 2009; 79: 73-8.
34. Kyoi T, Oka M, Noda K, et al. Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats. J Pharmacol Sci 2003; 93: 314-20.
35. Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003; 17: 111-7.
36. Mustonen H, Kiviluoto T, Paimela H, et al. Calcium signaling is involved in ethanol-induced volume decrease and gap junction closure in cultured rat gastric mucosal cells. Dig Dis Sci 2005; 50: 103-10.
37. 2+ signalling pathway in cultured rabbit gastric epithelial cells. Scand J Gastroenterol 2004; 39: 104-10.
38. Tatsumi Y, Tanino M, Kodama T, et al. Irsogladine maleate may preserve gastric mucosal hydrophobicity against ethanol in phospholipids independent way in rats. Jpn J Pharmacol 1998; 7: 293-9.
39. Korman MG, Hansky J, Eaves ER, et al. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871-4.
40. Graham DY, Opekun AR, Willingham FF, et al. Visible smallintestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-9.
41. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-41.
42. Satoh H, Igata N. Histamine H2 Receptor Antagonists, But Not Proton Pump Inhibitors, Aggravate NSAID-Induced Small Intestinal Ulcers in Arthritic Rats Gastroenterology 2009; 136 (Suppl 1): A-610
43. Wallace JL, Syer S, Denou E, et al. Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. Gastroenterology 2011; 141: 1314-22.
44. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115-27.
45. Takeuchi K, Tanaka A, Kato S, et al. Roles of COX inhibition in patho genesis of NSAID-induced small intestinal damage. Clinica Chimica Acta 2010; 411: 459-66.
46. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002; 47: 894-904.
47. 2 receptor antagonist, against loxoprofeninduced small intestinal lesions in rats. J Gastroenterol Hepatol 2010; 25: S111-8.
48. Amagase K, Ochi A, Kojyo A, et al. Prophylactic effect of monosodium glutamate against NSAID-induced enteropathy. J Pharmacol Sci 2012, in press
49. Asaoka D, Mori H, Nagahara A, et al. Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease. J Gastroenterol 2011; 46: 629-38.
50. Chen X, Oshima T, Tomita T, et al. Acidic bile salts modulate the squamous epithelial barrier function by modulating tight junction proteins. Am J Physiol 2011; 301: G203-9.
51. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
52. Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: The experience of two medical centers in capsule endoscopy. J Gastroenterol 2009; 44: 544-9.
53. Nonoyama K, Nakagawa K, Amagase K, et al. New method of inducing intestinal lesions in rats by intraduodenal administration of aspirin. J Gastroenterol Hepatol 2010; 25 (Suppl 1): S15-22.
54. Okabe S and Nakagawa K. Effect of irsoglandine maleate on the aspirin-induced intestinal lesions in rats. Jpn Pharmacol Ther 2010; 38: 297-302.
55. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 7571: 726-33.
56. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsterodal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
57. Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009; 48: 1725-30.
58. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
59. Lin KJ, Hernadez-Diaz S, Rodriguez LAG. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2111; 141: 71-9.
60. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
61. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors: Emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl 3): 27-36.
62. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-9.
63. de Jong JC, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-5.
64. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107-10.
65. Marshall JK, Rainsforf KD, James C, et al. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000; 14: 1451-7
66. Aihara E, Ise F, Ohashi Y, et al. Development of antral lesions inducd by alendronate in rat stomachs: Effect of irsogladine maleate. Pharmacol and Ther 2007; 35: 587-99.
67. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
68. Heaney RP. Calcium, daily products and osteoporosis. J Am Coll Nutr 2000; 19:83S-99S.
69. Ensurd KE, Duong T, Cauley JA, et al, for the Study of Osteoporotic Fractures Research Group. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 2000; 132: 345-53.